Comparison Between the Molecular and Crystal Structures of a Benzylpenicillin Ester and Its Corresponding Sulfoxide with Drastically Reduced Biological Activity
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Consideration of Antibacterial Medicines As Part Of
Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1. -
EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance . -
Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute-Care Hospitals
Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute- care hospitals Codebook v1.0 July 2016 Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute-care hospitals About Public Health England Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland Prepared by: PHE PPS England Team For queries relating to this document, please contact: [email protected] © Crown copyright 2016 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email [email protected]. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. Published July 2016 PHE publications gateway number: 2016185 Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute-care hospitals Contents About Public Health England 2 Recommended case finding algorithm for healthcare-associated -
European Surveillance of Healthcare-Associated Infections in Intensive Care Units
TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ............................................................................................................................................... -
Part I Betalactams, Aminoglycosides, Quinolones
Antibiotics – agents - part I betalactams, aminoglycosides, quinolones Vlastimil Jindrák Oddělení klinické mikrobiologie a antibiotická stanice Nemocnice Na Homolce, Praha 13.12. 2004 Antibiotika - katedra farmakologie 2. LF UK - 2 1 Antibiotics - antimicrobial agents • antibacterial agents • antifungal agents • antiviral agents • antiparasitic agents 13.12. 2004 Antibiotika - katedra farmakologie 2. LF UK - 2 2 Classification of antibiotics main groups of antibacterial agents betalactams chloramphenicol aminoglycosides tetracyklines quinolones rifamycins glycopeptides sulfonamides and trimethoprim macrolides, azalides polypeptides lincosamides nitroimidazoles ketolides nitrofurans streptogramines oxazolidinones 13.12. 2004 Antibiotika - katedra farmakologie 2. LF UK - 2 3 Classification of antibiotics antimycobacterial agents antibiotics active against mycobacteria streptomycine, rifampicin, fluoroquinolones specific antimycobacterial agents PAS (para-aminosalicylic acid) isoniazid ethambutol etionamid, pyrazinamid kapreomycin, cykloserin 13.12. 2004 Antibiotika - katedra farmakologie 2. LF UK - 2 4 Classification of antibiotics antifungal agents polyens amphotericin B, nystatine azoles fluconazole, itraconazole, voriconazole, ketoconazole echinocandines caspofungin others flucytosine, griseofulvin 13.12. 2004 Antibiotika - katedra farmakologie 2. LF UK - 2 5 Classification of antibiotics antiviral agents antivirotics nucleoside analogs: aciclovir, valaciclovir, famciclovir, ganciclovir neuraminidase inhibitors: oseltamivir, zanamivir -
Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals ................................................................................................................................................. -
Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD). -
Critically Important Antimicrobials for Human Medicine
Critically Important Antimicrobials for Human Medicine 4th Revision 2013 WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) Critically Important Antimicrobials for Human Medicine 4th Revision 2013 WHO Library Cataloguing-in-Publication Data Critically important antimicrobials for human medicine – 4th rev. 1.Anti-infective agents - classification. 2.Anti-infective agents - adverse effects. 3.Drug resistance, microbial - drug effects. 4.Risk management. 5.Humans. I.World Health Organization. ISBN 978 92 4 151146 9 (NLM classification: QV 250) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. -
Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) Critically Important Antimicrobials for Human Medicine 5th Revision 2016 Ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use Critically important antimicrobials for human medicine – 5th rev. ISBN 978-92-4-151222-0 © World Health Organization 2017, Updated in June 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/ igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Critically important antimicrobials for human medicine – 5th rev. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. -
Process of Production of Bacteriophage Compositions and Methods in Phage Therapy Field
(19) TZZ ZZZZ_T (11) EP 2 004 800 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 1/00 (2006.01) 15.01.2014 Bulletin 2014/03 (86) International application number: (21) Application number: 07734201.2 PCT/IB2007/000880 (22) Date of filing: 03.04.2007 (87) International publication number: WO 2007/113657 (11.10.2007 Gazette 2007/41) (54) PROCESS OF PRODUCTION OF BACTERIOPHAGE COMPOSITIONS AND METHODS IN PHAGE THERAPY FIELD VERFAHREN ZUR HERSTELLUNG VON BAKTERIOPHAGENZUSAMMENSETZUNGEN SOWIE VERFAHREN AUF DEM GEBIET DER PHAGENTHERAPIE PROCÉDÉ DE PRODUCTION DE COMPOSITIONS BACTÉRIOPHAGES ET PROCÉDÉS DANS LE DOMAINE DE LA THÉRAPIE PHAGIQUE (84) Designated Contracting States: (74) Representative: Novagraaf Technologies AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 122, rue Edouard Vaillant HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE 92593 Levallois-Perret Cedex (FR) SI SK TR (56) References cited: (30) Priority: 04.04.2006 US 788895 P WO-A-2004/052274 WO-A1-2004/062677 WO-A1-2005/009451 WO-A2-02/07742 (43) Date of publication of application: 24.12.2008 Bulletin 2008/52 • MATSUZAKISHIGENOBU ET AL: "Bacteriophage therapy: a revitalized therapy against bacterial (73) Proprietor: Krisch, Henry Morris infectious diseases" JOURNAL OF INFECTION 3960 Sierre (CH) AND CHEMOTHERAPY, vol. 11, no. 5, October 2005 (2005-10), pages 211-219, XP002443786 (72) Inventors: ISSN: 1341-321X • KRISCH, Henry, Morris • SKURNIK ET AL: "Phage therapy: Facts and F-31004 Toulouse Cedex 6 (FR) fiction" INTERNATIONAL JOURNAL OF • PRERE, Marie-Françoise MEDICAL MICROBIOLOGY, URBAN UND F-31200 Toulouse (FR) FISCHER, DE, vol. -
6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance . -
BETA-LACTAM ANTIBIOTICS Eduard Jirkovský, Přemysl Mladěnka
Projekt „Zvýšení kvality vzdělávání na UK a jeho relevance pro potřeby trhu práce-ESF Reg. č. CZ.02.2.69/0.0/0.0/16_015/0002362“, je financován z programu OP VVV BETA-LACTAM ANTIBIOTICS Eduard Jirkovský, Přemysl Mladěnka Content BETA-LACTAMS .......................................................................................................................................... 2 PENICILLINS ................................................................................................................................................ 2 CLASSIFICATION OF PENICILLINS ......................................................................................................................... 3 GENERAL ASPECTS OF PENICILLINS’ PHARMACOKINETIC ..................................................................................... 4 NATURAL PENICILLINS ........................................................................................................................................ 4 ANTISTAPHYLOCOCCAL PENICILLINS ................................................................................................................... 6 AMINOPENICILLINS .............................................................................................................................................. 8 ANTIPSEUDOMONAL PENICILLINS ........................................................................................................................ 9 ADVERSE EFFECTS OF ALL PENICILLINS ............................................................................................................